[go: up one dir, main page]

MA43131B1 - Compositions et procédés d'inhibition de l'activité de l'arginase - Google Patents

Compositions et procédés d'inhibition de l'activité de l'arginase

Info

Publication number
MA43131B1
MA43131B1 MA43131A MA43131A MA43131B1 MA 43131 B1 MA43131 B1 MA 43131B1 MA 43131 A MA43131 A MA 43131A MA 43131 A MA43131 A MA 43131A MA 43131 B1 MA43131 B1 MA 43131B1
Authority
MA
Morocco
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
compounds
Prior art date
Application number
MA43131A
Other languages
English (en)
Inventor
Eric Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MA43131B1 publication Critical patent/MA43131B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne une nouvelle classe de composés qui présentent une activité inhibitrice par rapport à l'arginase, et des compositions pharmaceutiques comprenant les composés de l'invention. L'invention concerne également des méthodes de traitement du cancer à l'aide des inhibiteurs d'arginase selon l'invention.
MA43131A 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase MA43131B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15
PCT/US2016/059342 WO2017075363A1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Publications (1)

Publication Number Publication Date
MA43131B1 true MA43131B1 (fr) 2020-07-29

Family

ID=58631120

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase

Country Status (36)

Country Link
US (4) US10065974B2 (fr)
EP (3) EP3693375B1 (fr)
JP (3) JP6833844B2 (fr)
KR (2) KR102434308B1 (fr)
CN (4) CN113201002A (fr)
AU (3) AU2016343656B2 (fr)
BR (3) BR112018008746B1 (fr)
CA (1) CA3003271A1 (fr)
CL (4) CL2018001134A1 (fr)
CO (1) CO2018004750A2 (fr)
CR (3) CR20180282A (fr)
CY (1) CY1123557T1 (fr)
DK (2) DK4011887T3 (fr)
EA (1) EA038276B1 (fr)
EC (1) ECSP18040250A (fr)
ES (3) ES2991555T3 (fr)
HR (1) HRP20201046T1 (fr)
HU (1) HUE054972T2 (fr)
IL (3) IL258731B (fr)
LT (1) LT3368541T (fr)
MA (2) MA50636A (fr)
MD (1) MD3368541T2 (fr)
MX (1) MX2018005294A (fr)
MY (1) MY201783A (fr)
NZ (1) NZ742742A (fr)
PH (2) PH12018500899B1 (fr)
PL (1) PL3368541T3 (fr)
PT (1) PT3368541T (fr)
RS (1) RS60695B1 (fr)
SG (4) SG10201911402YA (fr)
SI (1) SI3368541T1 (fr)
SM (1) SMT202000469T1 (fr)
TW (3) TWI710565B (fr)
UA (1) UA125289C2 (fr)
WO (1) WO2017075363A1 (fr)
ZA (4) ZA201803556B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
ES2568680T3 (es) 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CA3042878A1 (fr) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Polytherapies faisant appel a un inhibiteur d'arginase
MX378460B (es) * 2016-12-22 2025-03-10 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa.
BR112019023582A2 (pt) 2017-05-12 2020-06-02 Calithera Biosciences Inc. Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
WO2019120296A1 (fr) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de l'arginase
CA3091365A1 (fr) 2018-02-17 2019-08-22 Astrazeneca Ab Inhibiteurs de l'arginase et leurs procedes d'utilisation
EA202092086A1 (ru) 2018-03-05 2021-02-09 Аркус Байосайенсиз, Инк. Ингибиторы аргиназы
WO2019177873A1 (fr) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
PL3774843T3 (pl) 2018-03-29 2022-11-14 Molecure Sa Dipeptydowe pochodne piperydyny
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
AU2019379808C1 (en) 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020131598A1 (fr) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
US11420966B2 (en) * 2019-05-02 2022-08-23 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JP7579324B2 (ja) * 2019-07-23 2024-11-07 アストラゼネカ・アクチエボラーグ アルギナーゼ阻害剤及びその使用方法
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
TW202216662A (zh) * 2020-07-17 2022-05-01 美商英塞特公司 製備精胺酸酶抑制劑及其合成中間物之方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202416968A (zh) 2022-10-21 2024-05-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
CN121079299A (zh) 2023-03-13 2025-12-05 因赛特公司 作为激酶抑制剂的双环脲

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6403609B1 (en) 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
EP1049660A1 (fr) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions et procedes pour inhiber l'activite de l'arginase
CA2318920A1 (fr) 1998-01-29 1999-08-05 James W. Young Utilisations pharmaceutiques de (-)-bupropion optiquement pur
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
WO2002004465A1 (fr) 2000-07-06 2002-01-17 Fal Diagnostics Procedes et trousses de detection de composes d'arginine
CA2431080A1 (fr) 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20100080798A (ko) * 2007-10-12 2010-07-12 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
CA2722992A1 (fr) * 2008-05-05 2009-11-12 Schering Corporation Administration sequentielle d'agents de chimiotherapie pour le traitement du cancer
HUE046932T2 (hu) * 2009-01-26 2020-04-28 Univ Pennsylvania Argináz inhibitorok és felhasználási eljárások
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
ES2568680T3 (es) * 2010-10-26 2016-05-03 Mars, Incorporated Boratos como inhibidores de arginasa
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
BR112014009531A8 (pt) 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
WO2013158262A1 (fr) 2012-04-18 2013-10-24 Mars, Incorporated Analogues à cycle contraint en tant qu'inhibiteurs d'arginase
CN111329989A (zh) * 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
AU2014339816B2 (en) * 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
EP3270907A1 (fr) * 2015-03-20 2018-01-24 Sammy Oyoo OPIYO Utilisation de suramine et d'inhibiteurs de l'arginase dans une néoplasie maligne
MX385315B (es) * 2015-06-23 2025-03-14 Calithera Biosciences Inc Composiciones y metodos para inhibir actividad de arginasa.
TWI710565B (zh) 2015-10-30 2020-11-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性之組合物及方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
ZA201907093B (en) 2021-03-31
BR112018008746A2 (pt) 2018-10-30
JP7032583B2 (ja) 2022-03-08
CA3003271A1 (fr) 2017-05-04
TWI710565B (zh) 2020-11-21
BR112018008746B1 (pt) 2021-11-16
KR20220118559A (ko) 2022-08-25
DK4011887T3 (da) 2024-10-28
ES2991555T3 (es) 2024-12-04
PT3368541T (pt) 2020-07-06
IL288225A (en) 2022-01-01
EP3368541A1 (fr) 2018-09-05
MA50636A (fr) 2021-04-14
US10851118B2 (en) 2020-12-01
SG10201911406TA (en) 2020-01-30
US20180346489A1 (en) 2018-12-06
IL281503A (en) 2021-04-29
CR20210390A (es) 2021-10-19
CN108271371A (zh) 2018-07-10
CL2019000820A1 (es) 2019-08-09
CL2018001134A1 (es) 2018-10-26
CN113150016A (zh) 2021-07-23
PH12022551082A1 (en) 2023-03-13
CN108271371B (zh) 2021-02-09
CR20180282A (es) 2018-11-30
AU2016343656A1 (en) 2018-06-07
JP6833844B2 (ja) 2021-02-24
IL258731B (en) 2021-04-29
EP4011887B1 (fr) 2024-07-31
EP3693375B1 (fr) 2022-02-16
US10065974B2 (en) 2018-09-04
HRP20201046T1 (hr) 2020-10-16
CR20210389A (es) 2021-09-16
ZA201803556B (en) 2021-02-24
EP3693375A1 (fr) 2020-08-12
WO2017075363A1 (fr) 2017-05-04
SMT202000469T1 (it) 2020-11-10
ECSP18040250A (es) 2018-10-31
ZA201907092B (en) 2021-04-28
EA038276B1 (ru) 2021-08-04
BR122020022275B1 (pt) 2022-05-03
SG10201911402YA (en) 2020-02-27
SI3368541T1 (sl) 2020-10-30
CN113150015A (zh) 2021-07-23
JP2018533582A (ja) 2018-11-15
CL2019000821A1 (es) 2019-08-09
LT3368541T (lt) 2020-09-25
MX2018005294A (es) 2018-09-21
MD3368541T2 (ro) 2020-09-30
BR112018008746A8 (pt) 2019-02-26
EP4011887A1 (fr) 2022-06-15
PH12018500899A1 (en) 2018-10-29
AU2020286278B2 (en) 2022-03-17
TWI775556B (zh) 2022-08-21
TWI734630B (zh) 2021-07-21
EA201891057A1 (ru) 2018-12-28
US20200223872A1 (en) 2020-07-16
TW202146028A (zh) 2021-12-16
AU2016343656B2 (en) 2020-09-17
ES2808988T3 (es) 2021-03-02
CL2019000819A1 (es) 2019-08-09
TW202110858A (zh) 2021-03-16
SG11201802961PA (en) 2018-05-30
PH12018500899B1 (en) 2023-02-08
ZA201907091B (en) 2021-05-26
US20170121352A1 (en) 2017-05-04
HK1252560A1 (en) 2019-05-31
CY1123557T1 (el) 2022-03-24
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
AU2020286278A1 (en) 2021-01-14
KR20180084063A (ko) 2018-07-24
IL258731A (en) 2018-06-28
CO2018004750A2 (es) 2018-10-31
EP3368541B1 (fr) 2020-05-27
TW201726692A (zh) 2017-08-01
PL3368541T3 (pl) 2020-11-02
DK3368541T3 (da) 2020-06-29
BR122020022280B1 (pt) 2022-05-03
KR102434308B1 (ko) 2022-08-19
US10844080B2 (en) 2020-11-24
ES2910928T3 (es) 2022-05-17
MY201783A (en) 2024-03-18
JP2022071010A (ja) 2022-05-13
CN113201002A (zh) 2021-08-03
UA125289C2 (uk) 2022-02-16
JP2021075543A (ja) 2021-05-20
US20210061822A1 (en) 2021-03-04
IL281503B (en) 2022-01-01
HUE054972T2 (hu) 2021-10-28
AU2022203703A1 (en) 2022-06-16
RS60695B1 (sr) 2020-09-30
EP3368541A4 (fr) 2019-07-17

Similar Documents

Publication Publication Date Title
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
HK1220442A1 (zh) Ido抑制剂
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
PH12017500629A1 (en) Immuniregulatory agents
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
EA201790998A1 (ru) Иммуннорегуляторные агенты
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
MA47097B1 (fr) Compositions et procédés pour inhiber l'activité de l'arginase
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
MA40413B1 (fr) Dérivés de benzodiazépine cytotoxique
MA35151B1 (fr) Composés microarn et procédés pour la modulation de l'activité de mir-21
MA42711B1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2
MA41049B1 (fr) Compositions et méthodes d'inhibition de l'expression génique d'hao1 (hydroxyacide oxydase 1 (glycolate oxydase))
MA42681B1 (fr) Inhibiteurs de l'ezh2
MA46307A1 (fr) Composition et procédés pour moduler l'expression du facteur b du complément